Product Overview
Xeno Laboratories Femara is letrozole at 2.5 mg per tablet, the non-steroidal reversible aromatase inhibitor that clinicians know under that brand name and athletes usually meet as a fallback rather than a first choice. The pack is a support product with no anabolic or restorative role, and the strength is the reason for its reputation: whole tablets are rarely what a bodybuilding plan needs, and the tablet is routinely quartered.
How it compares with its two relatives shapes every dose decision later on the page. Arimidex is also reversible, while Aromasin is steroidal and irreversible. Letrozole belongs to the reversible family but is by far the most potent member, and at 2.5 mg daily the reference data show suppression of the aromatase enzyme of 98.9 to 99.1 percent. An effect of that size is not something a light converting course can absorb, which is why the standard advice is to hold it back and reach for it only when something has gone wrong.
Its natural home is therefore the same setting as the other inhibitors but with a narrower role, beside a course built on a converting androgen and judged by an estradiol reading rather than by how the user feels. The half-life of roughly two days means the level has to be built and cleared slowly, and the anti-doping picture is stricter here than for the other ancillaries: the substance sits on the prohibited list and is banned at all times in sport. Reported urine detection windows for non-steroidal inhibitors run from about ten days to more than thirty.
Dosage Protocol
These are reference steps for the substance, not a prescription, and every one of them assumes an estradiol test. The tablet is scored and is normally broken before it is swallowed.
| Beginner | A quarter tablet, 0.25-0.625 mg, on alternate days for four to six weeks |
| Intermediate | 0.625-1.25 mg on alternate days across six to eight weeks |
| Advanced | 1.25-2.5 mg daily, the top of the range and only against a confirmed high reading |
| Female | 2.5 mg daily belongs to medical ovulation induction under supervision, not to this context |
| Administration | Oral, at the same time each day, with the tablet divided for the low steps |
| Duration | Short stretches by blood result rather than open-ended use |
Dosing is built around the fraction, not the tablet. A quarter of 2.5 mg is about 0.625 mg, which is the practical opening step, and a knife or pill cutter is part of using the product properly. Getting the number wrong in either direction is costly: too little leaves estrogen where it was, and too much produces a dry, aching picture that takes days to fade because the half-life is measured in days, not hours.
Suggested Protocols
There are three ways the tablet shows up in practice, and in every one it accompanies a stack rather than standing alone. The lab sheet decides the rest.
What to Expect
- Estrogen-driven fluid and breast tenderness begin to settle within days of the first dose rather than weeks.
- The effect is often stronger than the user expects, because the suppression figure for a full daily dose is close to complete.
- Dry, sore joints and a smaller libido are the classic complaints, and the sources record them more often here than with anastrozole.
- An estradiol reading before and during use is the only way to avoid tipping into low-estrogen territory.
- A whole 2.5 mg tablet taken daily for sports-level control is almost always excessive.
- Use that stretches into months is associated with a bone density cost, so open-ended courses are not justified.
Side Effects and Management
Cycle Support and Follow-Up
This tablet never suppressed the axis, so there is no recovery step to attach to it. The question that matters is not when to start post-cycle work but when to stop the inhibitor after the course has finished.
For readers building the full picture, the milder estrogen control is described under Arimidex, the androgen-side product under Proviron, the gonadotropin step before recovery under HCG 5000 IU, and the recovery step itself under Tamox.
